Pharmacology · patient case question
What is buspirone used for, and what distinguishes it from the alternatives?
Patient case: Anxiety, before and during treatment
Patient: Female, 44 years old
Chief Complaint: “I need something to get me through this appointment.”
Background: Longstanding dental anxiety. She had oral sedation for an extraction two years ago and reports that she ‘remembers nothing at all’ about the appointment, although her husband says she talked to the dentist throughout. Her physician started BUSPIRONE three weeks ago for generalised anxiety disorder.
Vital Signs: BP 128/80 mmHg · HR 88 bpm
Findings: Non-restorable tooth #14 requiring extraction. She is visibly apprehensive but cooperative.
Show answer and explanation
Correct answer: B. An anxiolytic that is NOT a benzodiazepine — a 5-HT1A partial agonist with little sedation, no dependence, and no acute effect
- A. Antipsychotics carry extrapyramidal effects, tardive dyskinesia, orthostatic hypotension and xerostomia. Buspirone has none of that profile.
- B. CORRECT. BUSPIRONE is an anxiolytic for generalised anxiety disorder acting as a partial agonist at the 5-HT1A serotonin receptor. What matters clinically is what it does NOT do: little sedation, no meaningful potentiation of alcohol or other CNS depressants, no dependence or withdrawal syndrome, and — critically — NO ACUTE EFFECT. It takes two to four weeks to reach efficacy, which makes it useless for situational or procedural anxiety. So this patient's buspirone does nothing for today's appointment, and a separate plan is still required.
- C. Buspirone is specifically NOT a benzodiazepine, and rapid onset is precisely what it lacks — which is the clinically important point about it.
- D. The tricyclics are amitriptyline, imipramine and nortriptyline, used for depression and neuropathic pain. They cause marked xerostomia and an exaggerated response to injected vasoconstrictors, neither of which applies to buspirone.
Note: The dental relevance of buspirone is mostly NEGATIVE, which is why it appears in exam stems: no local anaesthetic dose modification, no vasoconstrictor restriction, minimal xerostomia, and no interaction of consequence. The trap is assuming that a patient already on an anxiolytic is covered for procedural anxiety. She is not.